semaj83/ctmatch_classification huggingface dataset:
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease (COPD) Current or former smokers with a diagnosis of COPD Having impaired lung function as measured by spirometry  History of asthma or nasal symptoms caused by hayfever No telephone Inability to record symptoms in an electronic diary (PDA)
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Obstructive Pulmonary Disease Sepsis Antibiotics All patients having a COPD (according to the definition of the American Thoracic Society) and having an acute exacerbation leading to an acute respiratory failure requiring the admission to ICU and mechanical ventilation The acute exacerbation of COPD is defined by increase in the frequency of cough, the volume and the purulence of expectoration and increase of baseline dyspnea. To be included, patients must have respiratory rate >30 cycles/min and one of the following blood gas (with blood gases performed right before the initiation of mechanical ventilation): PaC02 > 6kPa and arterial pH <7.30  Pneumonia documented with chest radiography Antibiotic treatment in the ten previous days of ICU admission Former in the study History of allergy to the quinolones and/or to trimethoprim sulfamethoxazole Pregnancy or breast feeding Severe chronic disease: heart, liver, kidney Known immunodeficiency (malignant hemopathy, AIDS...) Digestive disease which could affect the absorption of the drugs Concomitant infection which requires systemic antibiotic treatment
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Chronic Obstructive Pulmonary Disease Age 18-75 years Age, pack years, FEV1/FVC and FEV1% predicted must fit in one of the 5 groups described above Able to stop smoking for 10 days and start smoking 3-4 cigarettes within 1 hour Physically and mentally able to undergo the total study protocol Written informed consent  Participation in another study Alpha-1-antitrypsin deficiency Selected grade 1-3 co-morbidity listed in the ACE-27 Active pulmonary infection like tuberculosis, pneumonia, flue, tracheobronchitis Active extra-pulmonary infection like hepatitis A-C, cystitis, gastro-enteritis etc Pulmonary diseases like sarcoidosis, IPF, silicosis, hypersensitivity pneumonitis Life threatening diseases like carcinoma, AIDS (including HIV+), acute leukaemia etc Medication that may affect the results of the study: NSAID's, immunosuppressive agents like prednisolon, metotrexate, azathioprine,Acenocoumarol
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD FEV1/FVC < 70% FEV1 % predicted > 60%  Other major disease Asthma Currently taking inhaled corticosteroids oral corticosteroids in the last 3 month significant cardiovascular disease pregnancy/breast feeding current use of salmeterol or other long acting bronchodilator
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Chronic Obstructive Pulmonary Disease COPD patients All COPD patients who seek medical assistance at the clinic during the study period will be asked about COPD exacerbation related symptoms-medical history and then they will be included in the study if they satisfied all the following COPD diagnosis according to the GOLD Consensus Statement initiation of symptoms diagnostic for COPD exacerbation in the past 72 hours abstention from any new therapeutic intervention absence of any signs suggestive of severe exacerbation requiring hospitalization Control subjects Subjects who seek medical assistance at respiratory clinic for symptoms suggesting acute bronchitis (dyspnea, sputum production, purulence, wheeze, cough) medical history free of COPD, Asthma, pneumonia, other chronic respiratory disease or congestive cardiac failure initiation of symptoms in the past 72 hours  Patients with Asthma or other respiratory disease will be excluded from this study
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 45.0-75.0,  COPD stable stage II and III (GOLD) COPD, diagnosed 2 years ago and up  Heart failure Malignancy Immune suppressed
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Obstructive Pulmonary Disease (COPD) Smoking Smoking Cessation Chronic Bronchitis Emphysema Group A Healthy nonsmokers Enrolled in the "Normal" protocol #0005004439 "Evaluation of the Lungs of Normal (Smokers, Ex-smokers, Non-Smokers) Individuals with Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing, and Bronchial Wall Biopsy" Healthy according to the "Normal" protocol #0005004439 Willing and able to provide informed consent for the long term follow up study with repeated bronchoscopies Male and Female subject ≥18 years of age smoked < 100 cigarettes per lifetime and whose urine nicotine <2 ng/mL and urine cotinine <5 ng/mL, at entry into the study Group B Healthy current smokers Enrolled in the "Normal" protocol #0005004439  Groups A Unable to provide proper informed consent Drug and/or alcohol abuse within the past six months Individuals with asthma and with recurrent or recent (within three months) and/or acute pulmonary infection Allergy to lidocaine Significant kidney disease or subjects on dialysis Females who are pregnant or lactating or intending to become pregnant in the next 12 months Major depression or other significant psychiatric disorder HIV+ Subjects that have unstable coronary artery disease as evidenced by unstable angina, >Class II NYHA cardiac status, history of congestive heart failure or MI within the last 12 months
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Chronic Obstructive Pulmonary Disease Cardiovascular Disease Smoking Bronchodilation COPD Gold stage II-III (FEV1/FVC<0,70 and FEV1 30-80% of predicted value) Current cigarette smoking (at the time of performing the study) Willing to provide written informed consent Refrain from smoking and bronchodilators > 8 hours (depends on treatment) before the test Registered in one of the recruitment institutes  COPD gold stage I or IV Asthmatic component: History of asthma, present asthma by complaints, eosinophilia or reversibility ≥ 10% of predicted Unable to communicate Physically unable to perform any of the tests Non-COPD respiratory disorders Previous lung-volume reduction surgery and/or lung transplantation Evidence of alcohol, drug or solvent abuse Known α-1 antitrypsin deficiency
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COPD Diagnosis of COPD according to GOLD (FEV1/FVC<70%), classification into GOLD I (FEV1 70-100% predicted), GOLD II (FEV1 50-70% predicted), GOLD III (FEV1 30 predicted) or GOLD IV (FEV1 ≤ 30% predicted) Age ≥ 18 years Three or more exacerbations of COPD in one year for which a course of prednisone and/or antibiotic therapy was started Clinically stable during 1 month. Patients have to be free of COPD exacerbation or respiratory tract infection within a month prior to involvement in the study and they should not have received a high dose of systemic glucocorticoids or antibiotics in this period Informed consent  Use of antibiotics or high dose of systemic steroids within a month prior to involvement in the study Addition of inhalation steroids to the patient's therapy regimen, shortly before entering the study Pregnant or lactating women Allergy to macrolides Liver disease (alanine transaminase and/or aspartate transaminase levels 2 or more times the upper limit of normal) Asthma, defined as episodic symptoms of airflow obstruction which is reversible with bronchodilators, assessed with lung function testing Presence of a malignancy which is clinically active Bronchiectasis Malignancy of any kind for which the subject is under treatment or is being monitored as part of follow up after treatment Heart failure
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 40.0-90.0,  Chronic Obstructive Pulmonary Disease COPD diagnosis according to GOLD guidelines Hospitalization for any acute exacerbation of chronic obstructive pulmonary disease Failure of outpatient treatment Increasing of dyspnea in the last days Comorbidity that causes detriment of respiratory function  Life expectancy of less than 6 months Mechanical Ventilation Cardiovascular condition that causes exacerbation Immunosuppression Pulmonary infiltrates that suggest pneumonia Antibiotic treatment in the last month Pregnancy ECG with a large QT segment Hypokalemia Hepatic failure or renal failure
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 50.0-80.0,  Chronic Obstructive Pulmonary Disease Sixty stable moderate COPD patients (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2) requiring regular treatment with long-acting bronchodilators, according to international guidelines GOLD stage 2 COPD patients will be enrolled providing they were steroid-free for the last 4 months  Atopy Asthma Concomitant lung diseases (e.g. lung cancer) Acute infections of the respiratory tree in the previous 3 months including COPD exacerbation
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD Exacerbation Bronchitis Sputum C-Reactive Protein Age 40 or over. No upper age limit will be employed Written informed consent obtained according to the GOLD guideline. An exacerbation of COPD is defined as an event in the natural course of the disease characterized by a change in the patient's baseline dyspnoea, cough, and/or sputum that is beyond normal day-to-day variations, is acute in onset, and may warrant a change in regular medication in a patient with underlying COPD for hospital admission according to the GOLD: marked increase in symptoms (i.e. resting dyspnoea), severe underlying COPD, onset of new physical signs (cyanosis, edema), failure to respond to initial medical management, significant co morbidities, frequent exacerbations, newly occurring arrhythmias, diagnostic uncertainty Former of current smoker with a minimum smoking history of 10 pack years Patients have to be capable of ingesting oral medication Patients have to be mentally capable of participating in the study (able to complete questionnaires and perform lung function tests) Life expectancy ≥ 30 days  Pregnant or lactating women, or women of childbearing age not using an acceptable method of contraception Pretreatment with corticosteroids (cumulative dose >210 mg) for the present exacerbation Progression or new radiographic abnormalities on the chest X-ray or CT scan compatible with pneumonia bronchiectasis (HRCT confirmed) Cystic fibrosis Tuberculosis Immunodeficiency disorders such as AIDS, humoral immune defect, ciliary dysfunction etc., and the use of immunosuppressive drugs (>30 mg prednisolone/day maintenance dose or equivalent for more than 4 weeks) Recent or unresolved lung malignancy Other disease likely to require antibiotic therapy, such as recurrent sinusitis or urinary tract infection Significant gastrointestinal or other conditions that may affect study drug absorption
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD Signed informed consent Age ≥ 40 years Patients fulfilling for COPD according to the Global initiative for chronic obstructive pulmonary disease (GOLD) stage I or higher Smokers or ex-smokers of at least 10 pack-years Patients suffering an either Admitted to hospital due to (severe exacerbation) or Confirmed at GP (general practitioner) setting (moderate exacerbation) Definition Increase in respiratory symptoms requiring treatment with oral corticosteroids, antibiotics or both  Patients who have never smoked Patients with active long-term respiratory disease (e.g. bronchial asthma, cystic fibrosis, severe bronchiectasis, malignancy, restrictive lung diseases etc.) Exacerbation of COPD due to other causes such as pneumothorax and acute decompensated congestive heart failure Difficulties in communication (cognitive deterioration, sensorial disability, language barriers) Severe disease with poor vital prognosis (life length expectancy less than one year)
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Cough Male and female subjects, age 18 years and over History of cough for more than 8 weeks Normal chest x ray Chronic idiopathic cough or chronic cough resistant to treatment of specific triggers  Smoking status Current smokers Ex smokers with history of smoking > 20 pack years or those who have given up < 6 months ago Prohibited medications Use of medications likely to suppress / affect cough including codeine, morphine, pregabalin, gabapentin, amitriptylline, angiotensin converting enzyme inhibitors (type 1) and baclofen Use of any anti-arrhythmic medication Use of cimetidine, beta blockers, or diuretics Cardiovascular conditions Sinoatrial disease, bradycardia or all types of heart blocks History of ischaemic heart disease or heart failure
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Pulmonary Disease, Chronic Obstructive Type of subject: Outpatients Informed consent: Subjects must give their signed and dated written informed consent to participate Gender: Male or Female Age: 40 years of age or older at Visit 1 COPD diagnosis: Documented diagnosis of COPD at least 6 months prior to Visit 1 in accordance with the following definition by the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guideline: Post bronchodilator FEV1/FVC < 0.7 History of exacerbations: At least one COPD exacerbation which required the use of any additional treatment in the last 12 months prior to Visit 1 For subjects who were diagnosed between 6 to 12 months prior to Visit 1, they should have at least one COPD exacerbation that required the use of any additional treatment since diagnosis Tobacco use: Smokers or ex-smokers with a smoking history of more than 10 pack years  Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study Asthma: Subjects with a current diagnosis of asthma. Subjects with a prior history of asthma are eligible if COPD is the current diagnosis Non-compliance: Subjects unable to comply with any aspect of this study protocol or scheduled visits to the study centre